STRASBOURG, France, MONTREAL and BOSTON, November 13, 2025 — Leads & Copy — Domain Therapeutics has appointed Jean-Marie Cuillerot, M.D., a Boston-based pharmaceutical leader, as Chief Medical Officer (CMO) to advance its GPCR-targeting pipeline.
Dr. Cuillerot, based in Boston, brings extensive experience in pharmaceutical and biotech sectors, with a strong record in clinical development and regulatory strategy.
Earlier in his career, at Bristol-Myers Squibb, he led the lifecycle management of ipilimumab, the first approved immune checkpoint inhibitor for cancer, designing and leading Phase II and III clinical trials and supporting regulatory filings in the U.S. and Europe.
At EMD Serono, an affiliate of Merck Serono, Dr. Cuillerot directed clinical development of avelumab from pre-IND through global submissions, earning the Merck CEO Award.
Before joining Domain Therapeutics, Dr. Cuillerot served as CMO at Acrivon Therapeutics, Dragonfly Therapeutics, and Agenus, consistently advancing innovative therapies from early clinical stages toward regulatory milestones.
Sean A. MacDonald, Chief Executive Officer of Domain Therapeutics, expressed his delight in welcoming Dr. Cuillerot, citing his expertise in the biotechnology and pharmaceutical sector and proven track record in leading clinical teams and optimizing clinical strategies.
Dr. Cuillerot commented on Domain’s expertise in GPCR biology, noting its potential to deliver transformative outcomes for patients and modulate the immune system.
Dr. Cuillerot is joining Domain Therapeutics as it accelerates clinical progress, including the ongoing Phase I/II DOMISOL trial in Australia for DT-7012, a Treg-depleting anti-CCR8 monoclonal antibody. He will also guide the development of DT-9081, an EP4 receptor antagonist for solid tumors, and DT-9046, a first-in-class biased negative allosteric modulator of PAR2 in inflammation.
Domain Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic strategies targeting G protein-coupled receptors (GPCRs) to address unmet medical needs in immuno-oncology and inflammation. Its key programs include a Treg-depleting anti-CCR8 antibody and a biased antagonist of PAR2.
Domain leverages its proprietary drug discovery and development approach, founded on a unique platform and knowledge of GPCR receptor biology.
Contact:
N/A
Source: Domain Therapeutics
